bio-path holdings, inc.

A New Paradigm In Drug Development

Bio-Path presents a new paradigm in drug development in translating discoveries in oncology to clinical proof of concept. Bio-Path is currently commercializing revolutionary, patented liposomal delivery technology with two drug candidates ready for the clinic and a third siRNA candidate within 12 months of entering clinical trials. The near term mission of Bio-Path is to make its RNAi delivery the standard delivery technology in the pharmaceutical industry.

Highlights

Bio-Path has three license agreements with The University of Texas M. D. Anderson Cancer Center, the world's leading cancer center.

The management team and advisors at Bio-Path consist of pre-eminent scientists, clinicians and proven drug developers.

Bio-Path is developing a revolutionary, patented, liposomal drug delivery system with two drug candidates ready for the clinic and a third siRNA candidate within 12 months of entering clinical trials. Bio-Path’s drug delivery technology provides systemic distribution of nucleic acid drugs throughout the human body through simple intravenous transfusion. The delivery technology applies to both double stranded (siRNA) and single stranded (antisense) nucleic acid drugs. In addition, Bio-Path has licensed to develop liposome targeting technology. This technology has the potential to add a potential 5-8 fold advantage beyond the existing delivery technology.

Bio-Path’s drug delivery technology has the potential to revolutionize the treatment of cancer and other diseases where the targets of disease are well characterized.

Bio-Path’s existing portfolio of liposomal siRNA and antisense drug products provides confidence that the Company will have a strong current and future drug pipeline.

Effective February 12th, 2008, Bio-Path merged with an existing public corporation and is now a listed public entity, trading under the stock symbol BPTH. The Company has raised operating capital in three private financing rounds.